Arix Bioscience Debt 2024

Arix Bioscience Aktienanalyse

What does Arix Bioscience do?

Arix Bioscience PLC is a leading investment and management provider in the biotech industry. The company is focused on identifying, investing in, and growing emerging companies to develop groundbreaking therapies for patients worldwide. The firm was founded in 2016 in London, United Kingdom, and has since focused on collaborating with emerging biotech companies. Arix is now one of the fastest-growing biotech companies in the region, with locations in London, New York, and Zug, Switzerland. Arix Bioscience's business model is based on investing in young biotechnology companies and supporting their growth. The goal is to develop new drugs and therapies by driving innovation in the biotech industry, ultimately benefiting patients worldwide, including those with rare or incurable diseases. To achieve these goals, Arix Bioscience operates in three divisions: Investment, Management, and Discovery. The Investment division actively invests in young biotech companies that aim to develop and commercialize groundbreaking therapies and new diagnostic methods. The company not only provides financial resources but also has extensive experience in the biotech industry and a variety of contacts to offer advisory support when needed. The Management division focuses on effectively managing investments in young biotech companies to fully unleash their growth potential. Arix Bioscience assists these companies, for example, in finding suitable candidates for leadership positions, planning clinical trials, or exploring new markets. The Discovery division specifically targets the discovery and development of new therapies and medications. The company works directly with biotech startups to create a comprehensive value chain that spans from the discovery and exploration of drug molecules to clinical validation. To achieve these goals, Arix Bioscience collaborates closely with leading biotech startups and research institutions worldwide. The company has extensive relationships and networks in the biotech industry, allowing it to optimize the support it provides to its portfolios. Among the products provided by Arix Bioscience is a portfolio of drugs and therapies developed by the biotech companies in which Arix has invested. These portfolios include successful products such as the CD19 CAR-T therapy developed by Autolus Therapeutics, which is used in cancer treatment. Another example is MiroBio, a company in which Arix Bioscience has invested to develop a new medication for autoimmune diseases. Here too, Arix Bioscience has utilized its investment and management expertise to successfully support the company's growth. Overall, Arix Bioscience is a company with a clear focus on innovation and growth in the biotech industry. The company actively invests in emerging biotech startups and provides targeted management and comprehensive support to lead them to great successes. With its extensive experience, Arix Bioscience has become an important player in the development of new therapies and medications. Arix Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Arix Bioscience's Debt Structure

Arix Bioscience's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Arix Bioscience's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Arix Bioscience’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Arix Bioscience’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Arix Bioscience stock

What is the debt of Arix Bioscience this year?

Arix Bioscience has a debt level of -245.49 GBP this year.

What was the debt of Arix Bioscience compared to the previous year?

The debt of Arix Bioscience has increased by 83.07% compared to the previous year increased.

What are the consequences of high debt for investors in Arix Bioscience?

High debt can pose a risk for investors of Arix Bioscience, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Arix Bioscience?

Low debt means that Arix Bioscience has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Arix Bioscience affect the company?

An increase in debt of Arix Bioscience can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Arix Bioscience affect the company?

A reduction in debt of Arix Bioscience can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Arix Bioscience?

Some factors that can influence the debt of Arix Bioscience include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Arix Bioscience so important for investors?

The debts of Arix Bioscience are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Arix Bioscience take to change the debt?

To change the debt, Arix Bioscience can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Arix Bioscience pay?

Over the past 12 months, Arix Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arix Bioscience is expected to pay a dividend of 0 GBP.

What is the dividend yield of Arix Bioscience?

The current dividend yield of Arix Bioscience is .

When does Arix Bioscience pay dividends?

Arix Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arix Bioscience?

Arix Bioscience paid dividends every year for the past 0 years.

What is the dividend of Arix Bioscience?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arix Bioscience located?

Arix Bioscience is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Arix Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arix Bioscience from 9/8/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Arix Bioscience pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Arix Bioscience in the year 2023?

In the year 2023, Arix Bioscience distributed 0 GBP as dividends.

In which currency does Arix Bioscience pay out the dividend?

The dividends of Arix Bioscience are distributed in GBP.